211 related articles for article (PubMed ID: 26832753)
1. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
Hennig S; Svensson EM; Niebecker R; Fourie PB; Weiner MH; Bonora S; Peloquin CA; Gallicano K; Flexner C; Pym A; Vis P; Olliaro PL; McIlleron H; Karlsson MO
J Antimicrob Chemother; 2016 May; 71(5):1330-40. PubMed ID: 26832753
[TBL] [Abstract][Full Text] [Related]
2. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
[TBL] [Abstract][Full Text] [Related]
4. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A
J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400
[TBL] [Abstract][Full Text] [Related]
6. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
Khachi H; O'Connell R; Ladenheim D; Orkin C
J Antimicrob Chemother; 2009 Oct; 64(4):871-3. PubMed ID: 19628472
[No Abstract] [Full Text] [Related]
10. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
11. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
Regazzi M; Carvalho AC; Villani P; Matteelli A
Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
[TBL] [Abstract][Full Text] [Related]
12. Critical Review: What Dose of Rifabutin Is Recommended With Antiretroviral Therapy?
Yapa HM; Boffito M; Pozniak A
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):138-52. PubMed ID: 26855245
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
14. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Jenny-Avital ER; Joseph K
Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.
Tanuma J; Sano K; Teruya K; Watanabe K; Aoki T; Honda H; Yazaki H; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(8):e70611. PubMed ID: 23940604
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects.
Zhang X; Fettner S; Zwanziger E; Rowell L; Salgo M
Antimicrob Agents Chemother; 2011 Feb; 55(2):680-7. PubMed ID: 21135186
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
[TBL] [Abstract][Full Text] [Related]
18. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis.
Narita M; Stambaugh JJ; Hollender ES; Jones D; Pitchenik AE; Ashkin D
Clin Infect Dis; 2000 May; 30(5):779-83. PubMed ID: 10816148
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Matteelli A; Villani P; Carvalho AC; El-Hamad I; Cusato M; Apostoli A; Marcantoni C; Calabresi A; Dal Zoppo S; Bigoni S; Regazzi M
J Antimicrob Chemother; 2012 Oct; 67(10):2470-3. PubMed ID: 22678727
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis and HIV co-infection: a practical therapeutic approach.
Breen RA; Swaden L; Ballinger J; Lipman MC
Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
